KN026

KN026 is a monoclonal antibody developed by Shanghai JMT-Bio and CSPC Megalith Biopharmaceutical. Its target is HER2. ClinicalTrials.gov describes the intervention as: KN026 is an antibody targeting HER2, administered via intravenous infusion. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07441460 (A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer) and NCT06747338 (A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07441460, plans to enrol 1800 participants with primary completion expected 2034-08-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.